Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig in Inadequately Controlled COPD With an Eosinophilic Phenotype
NCT07190209Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Sep 2025
- Primary completion
- Nov 2029
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of lunsekimig in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started Sep 2025; status: recruiting.
02
Drugs
lunsekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07190209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190209.